Nick Pavlakis

Professor Nick Pavlakis is a Medical Oncologist affiliated with the University of Sydney's Northern Clinical School, Department of Medicine. His research focuses on oncology, particularly lung and colorectal cancers, with expertise in clinical trials and translational research. He has extensively published on targeted therapies, immunotherapy, and molecular diagnostics in cancer treatment.

His research interests include therapeutic approaches for advanced cancers, biomarker-driven treatments, and the integration of genomic profiling into clinical practice. He has led and contributed to major trials evaluating drugs like durvalumab, mobocertinib, and regorafenib in lung and gastric cancers.

Publications highlight advancements in immunotherapy combinations, biomarker identification (e.g., FDG PET/CT in neuroendocrine tumors), and management strategies for drug-resistant cancers. Collaborations span international trials and observational studies.

No scientific awards are explicitly listed, but his contributions are recognized through high-impact publications. He advises students in cancer research, including Alex DAVIS on co-mutation roles in lung cancer outcomes.

His work involves multidisciplinary teams and institutions, reflecting a commitment to translational research bridging clinical and experimental oncology.